Peptide Briefs

Questions about peptides? We've got you.
• What the studies actually show
• Evidence graded A–D
• Human data vs. animal data, sorted
Ed.D. | 2 yrs in China | Ki

[Peptide Briefs @PeptideBriefs]

Well, you know how every time you look up a peptide, one page says it works & the next says it doesn't?

Most people trying to learn hit that wall.

We're two teachers, so we built a library with a rubric: every compound graded A to D, with the work shown. https://t.co/LMfauruOmr

[Peptide Briefs @PeptideBriefs]

So: real human data, a clean safety signal, and a failed pivotal trial. That's a C.

Full page with references:

https://t.co/kMSi7oHB07

[Peptide Briefs @PeptideBriefs]

AOD-9604 gets a C from us. It's also one of the most tested compounds in the peptide world. Both are true, and the gap between them is the whole story.

[Peptide Briefs @PeptideBriefs]

Two caveats people skip. The efficacy trials used oral tablets, so that safety record doesn't automatically carry over to other routes. And "safe" plus "didn't beat placebo" is not a case for efficacy.

[Peptide Briefs @PeptideBriefs]

The evidence hierarchy in peptide land:
1.Randomized controlled trial
2.Pilot study
3.Animal study
4.A guy at the gym who "felt it in two days"

We grade the first three.

[Peptide Briefs @PeptideBriefs]

One line from the retatrutide Phase 3 paper that got little attention:

Stopping for adverse events was 4.1% at 4 mg, 6.5% at 9 mg and 11.2% at 12 mg. Placebo was 4.6%.

The lowest dose had fewer dropouts than placebo. The highest had more than double.

[Peptide Briefs @PeptideBriefs]

@VinnieSOfficial Amen

[Peptide Briefs @PeptideBriefs]

A vial with no lot number is just a small jar with a lot of confidence.

[Peptide Briefs @PeptideBriefs]

@Krysia830073 Got it. Thanks for doing these, by the way. Somebody has to.

[Peptide Briefs @PeptideBriefs]

@pepfanatics The court requested a certificate of analysis for the marriage. The lot number didn't match the vial.

[Peptide Briefs @PeptideBriefs]

@peptidedaily_ Worth noting the source: this is a company press release about conference presentations, so the full data and methods aren't published yet. Imaging studies like this are usually small. Do you know how many participants the fMRI arm had?

[Peptide Briefs @PeptideBriefs]

@DrSamuelBHume Good to see 25% used for retatrutide. That's the intention-to-treat figure from the NEJM paper. The 28.3% in most headlines is the efficacy estimand, which assumes everyone stayed on the drug.

[Peptide Briefs @PeptideBriefs]

@Krysia830073 This is the piece people need to read before trusting a chromatogram image. A trace on a certificate is only evidence if it came off the detector for that sample. A useful question for any lab: can you supply the raw data file for this report number?

[Peptide Briefs @PeptideBriefs]

@JCanNuSH @rn_flex Thanks for flagging this. The question I keep coming back to with tirzepatide and insulin sensitivity is how much is independent of weight loss. A GIP-only arm against dulaglutide is about the cleanest way to ask it. Did the combination look additive, or more than that?

[Peptide Briefs @PeptideBriefs]

@vedichi_ Good read of the ladder. The cost side points the same way: in TRIUMPH-1 (NEJM), stopping for adverse events was 4.1%, 6.5% and 11.2% at 4, 9 and 12 mg, vs 4.6% on placebo. So 9 to 12 adds under 2 points of weight loss here, with a much higher stopping rate there.

[Peptide Briefs @PeptideBriefs]

@foundmyfitness Good caveat on causation. One more for claims data: a diagnosis needs a test. Starting a GLP-1 means more visits and more labs, so some of the 12.4% may be a deficiency that was already there and finally got measured. Did the paper include a matched group not on the drug?